Company
ISOThrive
Microbiome Therapeutics
Also known as ISOThrive Inc
- Business model
- B2B
- Legal name
- ISOThrive Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Treating Chronic Disease Caused by Microbiome Dysbiosis. We develop novel, proprietary digestion-resistant carbohydrates that target specific bacteria to correct microbiome dysbiosis. Correcting dysbiosis is a potentially disease modifying MoA in numerous disease states of high unmet need.
Funding snapshot
- Total raised
- $17.4MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $8.1M2025-10-10
Funding rounds
- Round, 2025
- $8.1M2025-10-10, SEC form D sold, 12 investors
- Round, 2021
- $5.2M2021-01-22, SEC form D sold, 11 investors
- Round, 2019
- $4M2019-10-31, SEC form D sold, 25 investors
Loading relationship preview